SEARCH

SEARCH BY CITATION

References

  • 1
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology 1991; 13:619626. MEDLINE
  • 2
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: Serologic and clinical implications. J Hepatol 1992; 14:104111. MEDLINE
  • 3
    Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: What have we learned from our results? Hepatology 1991; 13:796799. MEDLINE
  • 4
    Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13:150157. MEDLINE
  • 5
    Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847. MEDLINE
  • 6
    Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813815. MEDLINE
  • 7
    Müller R, Gubernatis G, Farle M, Nichoff G, Klein H, Wittekind G, et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13:9096. MEDLINE
  • 8
    Lemmens HP, Langrehr JM, Blumhardt G, Lohmann R, Knopp M, Verschl J, et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. Transplant Proc 1994; 26:36223623. MEDLINE
  • 9
    Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knopp M, Neumann U, et al. Liver transplantation in hepatitis B surface antigen–positive patients with postoperative long-term immunoprophylaxis. Transplant Proc 1995; 2:418425.
  • 10
    Grazi GL, Mazziotti A, Sama C, Jovine E, Stefanini F, Paladini R, et al. Liver transplantation in HBsAg-positive HBV DNA–negative cirrhotics: Immunoprophylaxis and long-term outcome. Liver Transpl Surg 1996; 2:418425. MEDLINE
  • 11
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:13271333. MEDLINE
  • 12
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis cirrhosis with aggressive passive immunization. Transplantation 1996; 61:13581364. MEDLINE
  • 13
    Lake JR. Should liver transplantation be performed for patients with chronic hepatitis B? Liver Transpl Surg 1995; 1:260265. MEDLINE
  • 14
    Poterucha JL, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997; 125:805807.
  • 15
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213222. MEDLINE
  • 16
    Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer Zum, Büschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254263. MEDLINE
  • 17
    Samuel D, Roche B, Feray C, Arulnaden JI, Gigon M, Bismuth A, et al. Long-term results of liver transplantation in HBsAg-positive patients receiving anti-HBsAg passive immunoprophylaxis [abstract]. Hepatology 1998; 28:313A.
  • 18
    Lai CL, Chien RN, Leung NWY, Chang TT, Guang R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168. MEDLINE
  • 19
    Dienstag J, Schiff E, Wright T, Perillo R, Hann HW, Crowther L, et al. Lamivudine treatment for one year in previously untreated US hepatitis B patients: Histologic improvement and hepatitis B e antigen (HBeAg) seroconversion [abstract]. Gastroenterology 1998; 114:1235A.
  • 20
    Grellier L, Mutimer S, Ahmed M, Brown D, Burrough AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:12121215. MEDLINE
  • 21
    Perrilo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, et al. Lamivudine for hepatitis B after liver transplantation (OLT) [abstract]. Hepatology 1996; 24:182A.
  • 22
    Markowitz J, Pakrasi A, Hollis P, Martin P, Goldstein L, Busuttil R. Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients [abstract]. Hepatology 1996; 24:182A.
  • 23
    Allen MI, Deslaurier M, Andrews CW. Identification and characterization of mutation in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:16701677. MEDLINE
  • 24
    Ling R, Mutimer D, Ahmed M. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 3:711713.
  • 25
    Aye TT, Bartholomeusz A, Shaw T. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:11481153. MEDLINE
  • 26
    Bartholomew MM, Jansen RW, Jeffers LJ. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 9044:2022.
  • 27
    Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Lack of efficacy of lamivudine for HBV infection after liver transplantation [abstract]. Hepatology 1998; 28:262A.
  • 28
    Wainberg MA, Salomm H, Gu Z. Development of HIV-1 resistance to 2′3′-dideoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351357. MEDLINE
  • 29
    Tisdale M, Kemp SD, Parry NR. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′thicytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:56535656. MEDLINE
  • 30
    Villamil E, Kuhn M, Makowka L, Podesta L, Howard T, Sher L, et al. Quantitative anti-HBs titers during intramuscular (IM) hepatitis B immunoglobulin (HBIG) administration post–liver transplantation (LT) for hepatitis B [abstract]. Hepatology 1992; 16:49A.
  • 31
    Markowitz JS, Martin P, Conrad AJ, Markman JL, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585589. MEDLINE
  • 32
    Terrault NA, Wright TL, Roberts JP, Ascher NL. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients [abstract]. Hepatology 1998; 28:389A.
  • 33
    Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Substitution of lamivudine for long-term HBIG after liver transplantation for hepatitis B–related liver disease [abstract]. Hepatology 1998; 28:262A.
  • 34
    McCaughan G, Koorey D, Spencer J, Verran D, Chui AKK, Sheil AGR, et al. Prophylactic lamivudine and very low-dose HBIG prevent HBV recurrence post–liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss [abstract]. Hepatology 1998; 28:263A.